$LumiraDx (LMDXF.US)$ **Image Description:** The image appe...

**Image Description:**

The image appears to be a portion of a legal document, specifically a **Competition and Markets Authority (CMA)** report. The text discusses the **merger of LumiraDx and Roche**, focusing on whether the merger was necessary to prevent LumiraDx's exit from the UK market.

Key points include:

* Third parties acknowledged LumiraDx's technology as highly regarded.
* COVID-19 negatively impacted LumiraDx's financial position.
* Alternative funding options were available for LumiraDx, including debt or equity investment.
* Secured Creditors may have sought alternative funding rather than liquidation.
* The CMA believes that LumiraDx would have likely sought alternative funding absent the Merger.
* Third parties indicated sufficient funding could have been made available.
* The CMA concludes that LumiraDx's exit from the UK market was not inevitable.

Overall, the text suggests that the merger may not have been necessary to prevent LumiraDx's exit, as there were alternative funding options available.